Ivarmacitinib for advanced solid tumors after immunotherapy side effects
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This study tests a pill called Ivarmacitinib (a JAK inhibitor) for people with advanced solid tumors who had to stop immunotherapy because of side effects. The drug aims to calm the immune system and may help you restart cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stopped an immunotherapy drug (like a PD-1 or PD-L1 inhibitor) because of side effects.
- Your side effects from immunotherapy can be either still active (and you are on steroids) or mostly resolved (within 3 months of stopping).
- You need to have adequate organ function, such as normal blood counts, kidney, and liver tests.
- You must be willing to use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ivarmacitinib to see if it can help your body's immune system fight triple-negative breast cancer when immunotherapy alone has stopped working. It is a pill you take by mouth, and this study is in phase 2, meaning it's being tested for effectiveness in a larger group.
This study tests a new pill, ivarmacitinib, for people with moderate-to-severe rheumatoid arthritis who have not gotten enough relief from standard treatments. It aims to reduce joint pain and swelling and improve daily life.
This trial tests a new oral medication called Ivarmacitinib for people with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it helps reduce symptoms and improve skin condition.
This trial is testing an oral medication called ivarmacitinib, which may help protect the insulin-making cells in your pancreas and slow down the progression of type 1 diabetes. It is designed for people who have just been diagnosed with type 1 diabetes.
This trial tests an investigational drug, ivarmacitinib, to see if it can reduce inflammation and pain in people with polymyalgia rheumatica and help them avoid using steroids. The drug works by blocking certain immune system signals that cause joint and muscle stiffness.
This study compares a new pill (ivarmacitinib) to standard steroid treatment for people with mild-to-moderate lupus. It aims to see if the new drug can better control symptoms like joint pain and skin rashes while possibly reducing steroid side effects.
Hear when a new Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.